Implementation of Risk Prediction Models Using Electronic Health Data for Early Detection of Pancreatic Cancer: A Prospective Pilot Feasibility Study.

IF 3.5 2区 医学 Q2 ONCOLOGY
Cancer Medicine Pub Date : 2026-10-01 DOI:10.1002/cam4.72368
Bechien U Wu, Tiffany Q Luong, Eva Lustigova, Christie Jeon, Eric J Puttock, Rebecca H Moon, Mercedes A Munis, Wansu Chen
{"title":"Implementation of Risk Prediction Models Using Electronic Health Data for Early Detection of Pancreatic Cancer: A Prospective Pilot Feasibility Study.","authors":"Bechien U Wu, Tiffany Q Luong, Eva Lustigova, Christie Jeon, Eric J Puttock, Rebecca H Moon, Mercedes A Munis, Wansu Chen","doi":"10.1002/cam4.72368","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>We previously developed multiple machine-learning and regression-based risk prediction models using retrospective electronic health records (EHR) to estimate near-term risk of pancreatic cancer (PC). This pilot study aimed to assess the feasibility of an early detection strategy combining initial EHR-based risk prediction with downstream imaging and blood-based testing.</p><p><strong>Methods: </strong>This prospective study included adults aged 50-84 years with an estimated ≥ 1% 18-month risk of PC, identified between January 2021 and March 2023 using four previously validated models. Patients with a history or active suspicion of PC were excluded. Participants completed cross-sectional imaging and CA19-9 Labs at baseline and again at 18 months. Outcomes included enrollment rates, test completion rate, and burden of incidental findings.</p><p><strong>Results: </strong>Of 1251 eligible patients, 102 (8.2%) enrolled (median age 69 years [IQR 62-75]; 58% women; 48% Hispanic, 34% White, 11% Black, and 7% Asian). At baseline, 89 (87%) completed imaging and 98 (96%) completed CA19-9. At 18 months, 79% completed both imaging and CA19-9. Ten (10%) participants underwent additional clinical evaluations triggered by imaging findings. Evaluations included an endoscopic ultrasound, renal imaging, and FibroScan. CA19-9 results were normal in most participants, though 18% had elevated levels at baseline.</p><p><strong>Conclusions: </strong>Real-time EHR-based ML algorithms can be combined with blood- and imaging-based surveillance for early detection of PC with acceptable burden of incidental findings. However, improved patient engagement is a key aspect that will need to be addressed in order to successfully scale an AI-guided strategy for early detection.</p>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"15 10","pages":"e72368"},"PeriodicalIF":3.5000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13673295/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cam4.72368","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aims: We previously developed multiple machine-learning and regression-based risk prediction models using retrospective electronic health records (EHR) to estimate near-term risk of pancreatic cancer (PC). This pilot study aimed to assess the feasibility of an early detection strategy combining initial EHR-based risk prediction with downstream imaging and blood-based testing.

Methods: This prospective study included adults aged 50-84 years with an estimated ≥ 1% 18-month risk of PC, identified between January 2021 and March 2023 using four previously validated models. Patients with a history or active suspicion of PC were excluded. Participants completed cross-sectional imaging and CA19-9 Labs at baseline and again at 18 months. Outcomes included enrollment rates, test completion rate, and burden of incidental findings.

Results: Of 1251 eligible patients, 102 (8.2%) enrolled (median age 69 years [IQR 62-75]; 58% women; 48% Hispanic, 34% White, 11% Black, and 7% Asian). At baseline, 89 (87%) completed imaging and 98 (96%) completed CA19-9. At 18 months, 79% completed both imaging and CA19-9. Ten (10%) participants underwent additional clinical evaluations triggered by imaging findings. Evaluations included an endoscopic ultrasound, renal imaging, and FibroScan. CA19-9 results were normal in most participants, though 18% had elevated levels at baseline.

Conclusions: Real-time EHR-based ML algorithms can be combined with blood- and imaging-based surveillance for early detection of PC with acceptable burden of incidental findings. However, improved patient engagement is a key aspect that will need to be addressed in order to successfully scale an AI-guided strategy for early detection.

利用电子健康数据实现胰腺癌早期检测的风险预测模型:一项前瞻性试点可行性研究。
背景和目的:我们之前开发了多个基于机器学习和回归的风险预测模型,使用回顾性电子健康记录(EHR)来估计胰腺癌(PC)的近期风险。本试点研究旨在评估早期检测策略的可行性,该策略将基于ehr的初始风险预测与下游成像和血液检测相结合。方法:这项前瞻性研究纳入了年龄在50-84岁之间,估计18个月PC风险≥1%的成年人,在2021年1月至2023年3月期间使用四个先前验证的模型确定。排除有PC病史或积极怀疑PC的患者。参与者在基线和18个月时分别完成了横断面成像和CA19-9实验室检查。结果包括入学率、测试完成率和偶然发现的负担。结果:在1251例符合条件的患者中,102例(8.2%)入组(中位年龄69岁[IQR 62-75], 58%为女性,48%为西班牙裔,34%为白人,11%为黑人,7%为亚洲人)。基线时,89例(87%)完成影像学检查,98例(96%)完成CA19-9检查。18个月时,79%的患者完成了影像学检查和CA19-9检查。10名(10%)参与者接受了由影像学发现引发的额外临床评估。评估包括内窥镜超声、肾脏成像和纤维扫描。大多数参与者的CA19-9结果正常,尽管18%的人在基线水平升高。结论:基于实时ehr的ML算法可以与基于血液和图像的监测相结合,以早期发现具有可接受的意外发现负担的PC。然而,提高患者参与度是需要解决的一个关键方面,以便成功扩展人工智能指导的早期检测策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Medicine
Cancer Medicine ONCOLOGY-
CiteScore
5.50
自引率
2.50%
发文量
907
审稿时长
19 weeks
期刊介绍: Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书